Holst JJ - Search Results

1

Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity.

Christensen BJ, Iepsen EW, Lundgren J, Holm L, Madsbad S, Holst JJ, Torekov SS. Christensen BJ, et al. Among authors: holst jj. Obes Facts. 2017;10(6):633-647. doi: 10.1159/000481138. Epub 2017 Dec 6. Obes Facts. 2017. PMID: 29207396 Free PMC article.

2

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.

Orskov C, Jeppesen J, Madsbad S, Holst JJ. Orskov C, et al. Among authors: holst jj. J Clin Invest. 1991 Feb;87(2):415-23. doi: 10.1172/JCI115012. J Clin Invest. 1991. PMID: 1991827 Free PMC article.

3

On the effects of human galanin in man.

Holst JJ, Bersani M, Hvidberg A, Knigge U, Christiansen E, Madsbad S, Harling H, Kofod H. Holst JJ, et al. Diabetologia. 1993 Jul;36(7):653-7. doi: 10.1007/BF00404076. Diabetologia. 1993. PMID: 7689499

4

The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.

Toft-Nielson M, Madsbad S, Holst JJ. Toft-Nielson M, et al. Among authors: holst jj. Diabetes. 1996 May;45(5):552-6. doi: 10.2337/diab.45.5.552. Diabetes. 1996. PMID: 8621002

5

Metabolism of oral glucose in pancreas transplant recipients with normal and impaired glucose tolerance.

Christiansen E, Tibell A, Vølund AA, Holst JJ, Rasmussen K, Schäffer L, Madsbad S. Christiansen E, et al. Among authors: holst jj. J Clin Endocrinol Metab. 1997 Jul;82(7):2299-307. doi: 10.1210/jcem.82.7.4107. J Clin Endocrinol Metab. 1997. PMID: 9215311

6

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.

Toft-Nielsen M, Madsbad S, Holst JJ. Toft-Nielsen M, et al. Among authors: holst jj. Diabetologia. 1998 Oct;41(10):1180-6. doi: 10.1007/s001250051049. Diabetologia. 1998. PMID: 9794105

7

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ. Toft-Nielsen MB, et al. Among authors: holst jj. Diabetes Care. 1999 Jul;22(7):1137-43. doi: 10.2337/diacare.22.7.1137. Diabetes Care. 1999. PMID: 10388979 Clinical Trial.

8

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ. Vilsbøll T, et al. Among authors: holst jj. Diabetes Care. 2000 Jun;23(6):807-12. doi: 10.2337/diacare.23.6.807. Diabetes Care. 2000. PMID: 10841001

9

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Vilsbøll T, et al. Among authors: holst jj. Diabetes. 2001 Mar;50(3):609-13. doi: 10.2337/diabetes.50.3.609. Diabetes. 2001. PMID: 11246881

10

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Vilsbøll T, et al. Among authors: holst jj. Diabet Med. 2001 Feb;18(2):144-9. doi: 10.1046/j.1464-5491.2001.00424.x. Diabet Med. 2001. PMID: 11251679

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,781 results

Search Page

Filters